Friday, July 10, 2026

Drug profile · INN

glasdegib

glasdegib (DAURISMO) is a smoothened homolog antagonist.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX63
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — glasdegib
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

glasdegib (DAURISMO) is a smoothened homolog antagonist.

Key facts

INN glasdegib
Brand DAURISMO
Mechanism Smoothened homolog antagonist
Target Protein smoothened
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX63

Mechanism of action

Smoothened homolog antagonist

Primary target: Protein smoothened

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. C16-40 Phase 3 · George Institute for · Unresectable locally advanced and/or metastatic soft-tissue
  2. IRST204.07 Phase 3 · Istituto Gentili Italia · Acute myeloid leukemia
  3. Glasdegib Phase 2 · Jazz Pharmaceuticals Ireland · Acute Myelogenous Leukemia (AML) Due to Therapy

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is glasdegib?

glasdegib (DAURISMO) is a smoothened homolog antagonist.

What is the brand name for glasdegib?

DAURISMO is a marketed brand name for glasdegib. Check FDA Drugs@FDA for the current US label holder and prescribing information.